The Third Annual Enabling Point-of-Care Diagnostics Conference will present a unique opportunity to network with life science executives attending the August 10-11, 2009 meeting at the Ritz Carlton Hotel in Washington D.C. Listen to experts in the field discuss how information provided at the point-of-care can be done efficiently to provide disease management effectively.
Attendees will hear Mark N. Blatt M.D. Director, Healthcare Industry Solutions, Digital Health Group, Intel Corporation discuss new clinical and business trends that are empowering clinicians in the developed world to provide care directly to the home.
Craig Lehmann, PhD, Interim Executive Dean of the Health Sciences Center, Dean of the School of Health Technology and Management, and Professor of the Clinical Laboratory Sciences at Stony Brook University, reports that of the 58 million deaths in developed and developing countries, approximately 35 million will be a direct result of heart disease, stroke, cancer, chronic respiratory diseases, diabetes and is expected to increase by 17 percent in the future. His presentation will discuss the use of e-health and point-of-care technology in community health environments in the U.S. and in Kenya.
When point-of care is needed to provide disease management, Becky Clarke, Executive Vice President, Telco will detail how to effectively transmit data, integrate the data, and then communicate the data to clinicians.
The next generation point-of-care Closed Unit-Dose Assay (CUDA) will be described by Richard Lee, PhD, Senior Manager, Development, Gen-Probe, Inc. The platform uses actuator-driven fluidic movement to perform a complete sample-to-result molecular diagnostic assay in one hour.
Case studies in disease management will be presented on day two. Joseph M. Campos, PhD, Director, Microbiology Laboratory, Molecular Diagnostics Laboratory and Laboratory Informatics, at Children’s National Medical Center, and a Professor at George Washington University Medical Center, will present case studies that illustrate the value of point-of-care testing in the hospital environment.
New Products, new companies, and new technologies will be on display. Thomas Lowery PhD, Director of Research, Assay Development, at T2 Biosystems, will discuss a next generation point-of-care diagnostic platform that the company has pioneered. The compact universal detection platform is able to demonstrate sensitive measurements of DNA, proteins, and many other target analytes. Because of the magnetic-based detection system, the usual interference in optical assays does not occur. This unique combination of technologies allows for a multiplex and multi-analyte (DNA and protein) system to rapidly quantify biomarkers on dirty samples.
The “Enabling Point-of-Care Diagnostics meeting is part of the Cambridge Healthtech Institutes Premiere “Next Generation Dx Summit” Other meetings offered the same week at the Ritz Carlton in Washington D.C. include Trends in Cancer Diagnostics, Molecular Diagnostics for Infectious Diseases, and Clinical Adoption of Next Generation Diagnostics, plus there will be several Pre-Conference Symposiums.
For more information, go to www.nextgenerationdx.com. To register, go to https://chidb.com/register/2009/adx/reg.asp or email firstname.lastname@example.org , or telephone (781)-972-5400 Option 1.